Can an experimental pill boost chemotherapy's power against stubborn uterine cancer?

NCT ID NCT07737795

Not yet recruiting Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding an experimental drug called OK-1 to the standard chemotherapy paclitaxel can shrink tumors in people with advanced or recurrent endometrial cancer. Participants take OK-1 capsules twice daily along with weekly intravenous paclitaxel. The study aims to see if the combination is safe and how many patients respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called OK-1 combined with the chemotherapy drug paclitaxel
What this could lead to: If it works, this combination could offer a new treatment option for people with recurrent endometrial cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits are uncertain. The combination may cause significant side effects, and not all patients may tolerate it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER

Contacts and locations

Locations

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.